You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Article metrics

Article menu
Cardiovascular and metabolic risk
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

 

Online download statistics by month:

Online download statistics by month: October 2021 to March 2024

AbstractFullPdf
Oct 2021789789307
Nov 2021422417167
Dec 2021281271127
Jan 202220520788
Feb 202214114776
Mar 202220922295
Apr 202225926475
May 202218118287
Jun 202214414464
Jul 202214914558
Aug 202215014539
Sep 202217316779
Oct 202217218778
Nov 202219420664
Dec 202212912357
Jan 202310410340
Feb 202312112051
Mar 202310510553
Apr 2023757666
May 2023958942
Jul 2023595629
Aug 2023767333
Sep 2023555525
Oct 2023706621
Nov 20231236836
Dec 20231316925
Jan 2024715532
Feb 2024614430
Mar 2024826950
Total482646641994